Evestia Clinical Limited is headquartered in Letchworth Garden City, Hertfordshire, United Kingdom, and describes itself as a global specialist CRO partner for biotechs and beyond. The company positions itself as agile and personalised, with experts engaged from day one of a programme and a focus on streamlining processes and removing roadblocks in complex trials. It holds Great Place to Work certification in the UK, Germany, and the USA.

The company has grown through combination with other specialist businesses. ICRC-Weyer joined Evestia Clinical, and the company published a six-month review of the combined team’s progress. The website does not state a founding date, headcount, or full location list on the pages reviewed, although it has a dedicated locations page. It also publishes thought leadership, including pieces on ICH E6(R3) readiness and integrated clinical development, and operates a board and a strategic advisory board.

Key Products and Services

Clinical Operations

• Project management — expert project leadership across clinical trials
• Site management — management of clinical trial sites through to successful delivery
• Clinical monitoring — personalised oversight from initiation to completion

Regulatory and Quality

• Regulatory services — regulatory guidance to support programme approvals
• Quality assurance services — quality oversight and audit support for clinical trials

Data and Scientific Services

• Data management and biostatistics — analytical support across all trial phases
• Medical affairs and medical writing
• Pharmacokinetics expertise — PK analyses and models to support development decisions

Safety

• Pharmacovigilance — drug safety support for therapies in development and on the market

Flexible Delivery

• Functional service provider (FSP) solutions adaptable to sponsor needs, alongside full-service delivery

Therapeutic Experience

• Oncology, rare disease, neurology, immunology, and inflammation

Evestia Clinical occupies the mid-sized specialist CRO segment, targeting biotech sponsors that want senior, personalised support in complex indications rather than the scale of the largest global CROs. Its therapeutic focus on oncology, rare disease, neurology, immunology, and inflammation matches the areas where specialist trial design and site experience matter most. Offering both full-service and FSP models gives sponsors flexibility to outsource whole studies or individual functions. Its recent combination with ICRC-Weyer, and its public commentary on ICH E6(R3), suggest it is consolidating capabilities and positioning around quality-focused delivery. Because the site gives no headcount, trial volumes, or client names, its scale is hard to judge from public information.